{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:26:44Z","timestamp":1789698404687,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T00:00:00Z","timestamp":1519776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.steroids.2018.02.010","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T06:06:46Z","timestamp":1520489206000},"page":"43-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes"],"prefix":"10.1016","volume":"134","author":[{"given":"Eric P.","family":"Hoffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Riddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime A.","family":"Siegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Dickerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav","family":"Backonja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanneboyina","family":"Nagaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Gordish-Dressman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse M.","family":"Damsker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"McCall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.steroids.2018.02.010_b0005","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1210\/me.2013-1334","article-title":"Minireview: dynamic structures of nuclear hormone receptors: new promises and challenges","volume":"28","author":"Simons","year":"2014","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.steroids.2018.02.010_b0010","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.yfrne.2007.10.004","article-title":"The effects of non-genomic glucocorticoid mechanisms on bodily functions and the central neural system. A critical evaluation of findings","volume":"29","author":"Haller","year":"2008","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.steroids.2018.02.010_b0015","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids\u2014new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.steroids.2018.02.010_b0020","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.steroids.2018.02.010_b0025","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1530\/EJE-11-0751","article-title":"Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals","volume":"166","author":"Kauh","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.steroids.2018.02.010_b0030","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12891-016-1135-3","article-title":"Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover study","volume":"17","author":"Fleishaker","year":"2016","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.steroids.2018.02.010_b0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","article-title":"Mechanisms involved in the side effects of glucocorticoids","volume":"96","author":"Sch\u00e4cke","year":"2002","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.steroids.2018.02.010_b0040","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.bone.2012.10.036","article-title":"High resolution quantitative computed tomography-based assessment of trabecular microstructure and strength estimates by finite-element analysis of the spine, but not DXA, reflects vertebral fracture status in men with glucocorticoid-induced osteoporosis","volume":"52","author":"Graeff","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.steroids.2018.02.010_b0045","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1176\/appi.ajp.2014.13091264","article-title":"Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects","volume":"171","author":"Judd","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.steroids.2018.02.010_b0050","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0092-8674(04)00400-3","article-title":"Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy","volume":"117","author":"Sandri","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.steroids.2018.02.010_b0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1440-1797.2003.00215.x","article-title":"Glucocorticoids and the kidney","volume":"8","author":"Mangos","year":"2003","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.steroids.2018.02.010_b0060","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/archdischild-2016-311223","article-title":"Symptomatic adrenal suppression among children in Canada","volume":"102","author":"Goldbloom","year":"2017","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.steroids.2018.02.010_b0065","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1096\/fj.14-254755","article-title":"Targeting glucocorticoid side effects: selective glucocorticoid receptor modulator or glucocorticoid-induced leucine zipper? A perspective","volume":"28","author":"Ayroldi","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.steroids.2018.02.010_b0070","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.bmc.2013.02.009","article-title":"VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid","volume":"21","author":"Reeves","year":"2013","journal-title":"Bioorg. Med. Chem."},{"issue":"2013","key":"10.1016\/j.steroids.2018.02.010_b0075","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/emmm.201302621","article-title":"VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects","volume":"5","author":"Heier","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.steroids.2018.02.010_b0080","doi-asserted-by":"crossref","first-page":"e63871","DOI":"10.1371\/journal.pone.0063871","article-title":"VBP15, a glucocorticoid analogue, is effective at reducing allergic lung inflammation in mice","volume":"8","author":"Damsker","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.steroids.2018.02.010_b0085","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10571-014-0133-y","article-title":"VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis","volume":"35","author":"Dillingham","year":"2015","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.steroids.2018.02.010_b0090","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00011-016-0956-8","article-title":"VBP15, a novel dissociative steroid compound, reduces NF\u03baB-induced expression of inflammatory cytokines in vitro and symptoms of murine trinitrobenzene sulfonic acid-induced colitis","volume":"65","author":"Damsker","year":"2016","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.steroids.2018.02.010_b0095","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pupt.2016.04.004","article-title":"A novel dissociative steroid VBP15 reduces MUC5AC gene expression in airway epithelial cells but lacks the GRE mediated transcriptional properties of dexamethasone","volume":"38","author":"Garvin","year":"2016","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.steroids.2018.02.010_b0100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1474-4422(14)70318-7","article-title":"Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial","volume":"14","author":"Raman","year":"2015","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.steroids.2018.02.010_b0105","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12931-015-0293-4","article-title":"Pharmacologically-induced mitotic synchrony in airway epithelial cells as a mechanism of action of anti-inflammatory drugs","volume":"16","author":"Freishtat","year":"2015","journal-title":"Respir. Res."},{"key":"10.1016\/j.steroids.2018.02.010_b0110","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1165\/rcmb.2013-0396OC","article-title":"Mitotic asynchrony induces transforming growth factor-\u03b21 secretion from airway epithelium","volume":"51","author":"Alcala","year":"2014","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"10.1016\/j.steroids.2018.02.010_b0115","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1083\/jcb.201402079","article-title":"Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy","volume":"207","author":"Dadgar","year":"2014","journal-title":"J. Cell. Biol."},{"issue":"2017","key":"10.1016\/j.steroids.2018.02.010_b0120","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1056\/NEJMra1612575","article-title":"Academic, foundation, and industry collaboration in finding new therapies","volume":"376","author":"Ramsey","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.steroids.2018.02.010_b0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1107\/S2053229614024218","article-title":"Crystal structure refinement with SHELXL","volume":"71","author":"Sheldrick","year":"2015","journal-title":"Acta Crystallogr. C Struct. Chem."},{"key":"10.1016\/j.steroids.2018.02.010_b0130","doi-asserted-by":"crossref","first-page":"31727","DOI":"10.1038\/srep31727","article-title":"Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children","volume":"6","author":"Hathout","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.steroids.2018.02.010_b0135","doi-asserted-by":"crossref","first-page":"R49","DOI":"10.1530\/JOE-14-0373","article-title":"Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes","volume":"223","author":"Rafacho","year":"2014","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.steroids.2018.02.010_b0140","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jbspin.2006.10.009","article-title":"Systemic effects of epidural and intra-articular glucocorticoid injections in diabetic and non-diabetic patients","volume":"74","author":"Younes","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.steroids.2018.02.010_b0145","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.tem.2013.12.006","article-title":"Glucocorticoids and bone: local effects and systemic implications","volume":"25","author":"Henneicke","year":"2014","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.steroids.2018.02.010_b0150","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bone.2015.05.038","article-title":"Glucocorticoids, bone and energy metabolism","volume":"82","author":"Cooper","year":"2016","journal-title":"Bone"},{"issue":"1995","key":"10.1016\/j.steroids.2018.02.010_b0155","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1126\/science.270.5234.283","article-title":"Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids","volume":"270","author":"Scheinman","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.steroids.2018.02.010_b0160","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/cg700866f","article-title":"Structural, thermodynamic, and kinetic aspects of the polymorphism and pseudopolymorphism of prednisolone (11,17\u03b1,21-Trihydroxy-1,4-pregnadien-3,20-dion)","volume":"8","author":"Suitchmezian","year":"2008","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.steroids.2018.02.010_b0165","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00198-016-3774-5","article-title":"The time to and determinants of first fractures in boys with Duchenne muscular dystrophy","volume":"28","author":"Ma","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.steroids.2018.02.010_b0170","article-title":"Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy","volume":"1","author":"Bell","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.steroids.2018.02.010_b0175","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0039-128X(03)00030-8","article-title":"Glucocorticoid receptor interactions with glucocorticoids: evaluation by molecular modeling and functional analysis of glucocorticoid receptor mutants","volume":"68","author":"Hammer","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2018.02.010_b0180","doi-asserted-by":"crossref","first-page":"C155","DOI":"10.1152\/ajpcell.00269.2016","article-title":"Renin-angiotensin-aldosterone system inhibitors improve membrane stability and change gene-expression profiles in dystrophic skeletal muscles","volume":"312","author":"Chadwick","year":"2017","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"10.1016\/j.steroids.2018.02.010_b0185","first-page":"00128","article-title":"Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle.","author":"Chadwick","year":"2016","journal-title":"Physiol. Genom."}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X1830045X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X1830045X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T12:52:16Z","timestamp":1535028736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X1830045X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":37,"alternative-id":["S0039128X1830045X"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2018.02.010","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2018.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}